1. Understanding Treatment Goals for Patients With Onychomycosis

3. Program Goals

4. What Is Onychomycosis?

5. What Is Onychomycosis? (cont)

6. Mild Onychomycosis

7. Moderate Onychomycosis

8. Severe Onychomycosis With Tinea Pedis

9. Presentation of Onychomycosis

10. Treatment Challenges

11. Treatment Challenges (cont)

13. Why Treat Onychomycosis? (cont)

14. Why Treat Onychomycosis? (cont)

15. Clinical Trial End Points: Complete Cure

16. Clinical Trial End Points: Mycologic Cure

17. Clinical Trial End Points: Questions and Issues

18. A New Era

19. Oral Antifungals

20. Oral Antifungals (cont)

22. Oral Antifungals: Safety Issues

23. Oral Antifungals: Safety Issues

24. Ciclopirox

25. New Topical Antifungals

26. New Topical Antifungals (cont)

27. Efinaconazole

28. Efinaconazole (cont)

29. Efinaconazole Cure Rates

30. Efinaconazole Cure Rates (Cont)

31. Efinaconazole Safety

32. Clinical Trials: Tavaborole

33. Tavaborole Cure Rates

34. Tavaborole Cure Rates (cont)

35. Tavaborole Safety

36. New Antifungal Solutions in Practice

37. Abbreviations

38. References

39. References (cont)

40. References (cont)

41. References (cont)